Protalix BioTherapeutics, Inc. (PLX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PLX Revenue Growth
Revenue Breakdown (FY 2025)
PLX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
PLX Revenue Analysis (2014–2025)
As of May 8, 2026, Protalix BioTherapeutics, Inc. (PLX) generated trailing twelve-month (TTM) revenue of $52.7 million, reflecting significant decline in growth of -49.9% year-over-year. The most recent quarter (Q4 2025) recorded $9.1 million in revenue, down 48.9% sequentially.
Looking at the longer-term picture, PLX's 5-year compound annual growth rate (CAGR) stands at -3.5%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $65.5 million in 2023.
Revenue diversification analysis shows PLX's business is primarily driven by Product (98%), and License and Service (2%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and SRPT (-2.2% YoY), PLX has underperformed the peer group in terms of revenue growth. Compare PLX vs RARE →
PLX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PLXCurrent | $53M | -49.9% | -3.5% | -10.4% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 SRPT | $2.2B | -2.2% | +32.4% | -29.9% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 KRYS | $389M | +25.1% | - | 41.5% |
PLX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $52.7M | -1.2% | $25.8M | 48.8% | $-5,500,000 | -10.4% |
| 2024 | $53.4M | -18.5% | $29.1M | 54.5% | $3.9M | 7.3% |
| 2023 | $65.5M | +37.5% | $42.5M | 64.9% | $10.5M | 16.0% |
| 2022 | $47.6M | +24.2% | $28.0M | 58.9% | $-13,014,000 | -27.3% |
| 2021 | $38.4M | -39.0% | $22.0M | 57.4% | $-20,462,000 | -53.4% |
| 2020 | $62.9M | +15.0% | $52.0M | 82.7% | $2.7M | 4.3% |
| 2019 | $54.7M | +59.7% | $43.8M | 80.1% | $-10,717,000 | -19.6% |
| 2018 | $34.2M | +62.4% | $24.9M | 72.8% | $-19,308,000 | -56.4% |
| 2017 | $21.1M | +129.1% | $5.8M | 27.7% | $-34,517,000 | -163.8% |
| 2016 | $9.2M | +110.8% | $801K | 8.7% | $-33,163,000 | -360.5% |
See PLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PLX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPLX — Frequently Asked Questions
Quick answers to the most common questions about buying PLX stock.
Is PLX's revenue growth accelerating or slowing?
PLX revenue declined -49.9% year-over-year, contrasting with the 5-year CAGR of -3.5%. TTM revenue fell to $53M. This reverses the prior growth trend.
What is PLX's long-term revenue growth rate?
Protalix BioTherapeutics, Inc.'s 5-year revenue CAGR of -3.5% reflects the variable expansion pattern. Current YoY growth of -49.9% is below this long-term average.
How is PLX's revenue distributed by segment?
PLX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.